

MNKD Products & Pipeline

Cardiometabolic

Orphan Lung

Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval
Afrezza® (insulin human) Inhalation Powder	T1DM / T2DM (aged 6 and older)					Marketed
V-Go® All-in-One Insulin Delivery Patch	T1DM / T2DM (adults)					Marketed
Furoscix® / Furoscix ReadyFlow™ (furosemide injection)	Edema from HF / CKD					Marketed
Bumetanide DPI (MNKD-701)	Edema from HF / CKD	Pre-Clinical				
Tyvaso DPI® (treprostinil) Inhalation Powder (marketed by United Therapeutics)	PAH / PH-ILD					Marketed
Nintedanib DPI (MNKD-201)	IPF, PPF			Phase 2 (INFLO-2 study)		
Ralinepag DPI (MNKD-1501; collaboration with United Therapeutics)	PAH, PH-ILD, IPF, PPF	Pre-Clinical				

KEY: T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; HF = heart failure; CKD = chronic kidney disease; PAH = pulmonary arterial hypertension; PH-ILD = pulmonary hypertension associated with interstitial lung disease; IPF = idiopathic pulmonary fibrosis; PPF = progressive pulmonary fibrosis.